

Zen Pro

Food Supplement with Probiotics and Vitamins B5 & B6
30 capsules

Net weight ≥ 9.75 g e

WHAT IS ZEN PRO?

Zen Pro is a food supplement in capsule form containing a clinically studied Bifizen® probiotic blend combined with vitamins B5 and B6. It is designed to support intestinal flora balance and contributes to psychological wellbeing, mental focus, and healthy nervous system function. Research shows that stress and anxiety have been associated to alteration in the gut microbiota composition¹⁻¹⁰.

Bifizen® probiotic blend has proven to be more effective than single strains in affecting positively epithelial intestinal barrier, ROS production and cell viability in different cellular axis models^{10,11}, suggesting that the mix provides a better strategy of treatment. In three distinct RCTs, the BIFIZEN® probiotic blend showcased remarkable outcomes related to mood, sleep quality and overall well-being, with the confirmation of the influence of BIFIZEN® probiotic blend on the gut microbiota composition as well as urine and serum metabolome^{12,13,14,15,16}.

WHY CHOOSE ZEN PRO?

Contains the clinically studied Bifizen® probiotic blend, four unique strains ensuring stability and targeted intestinal release.

Supports intestinal flora balance and gut health, essential for general wellbeing.

Vitamin B5 contributes to normal mental performance

Vitamin B6 contributes to normal psychological function and normal functioning of the nervous system.

Together, these nutrients and probiotics help support mood balance and improved sleep quality through gut-brain axis modulation.

INFORMATION ON COMPOSITION

Ingredients: Capsule (hydroxypropyl methyl cellulose), silicon dioxide, Bifizen® probiotic blend (*Limosilactobacillus fermentum* LF16 (DSM 26956), *Lactocaseibacillus rhamnosus* LR06 (DSM 21981), *Lactiplantibacillus plantarum* LP01 (LMG P-21021), *Bifidobacterium longum* 04 (DSM 23233)), Vitamin B5 (calcium pantothenate), Vitamin B6 (pyridoxine hydrochloride), maltodextrin.

ALLERGEN-FREE CERTIFICATION

Certified *allergen-free: contains no gluten, dairy, soy, nuts, eggs, fish, shellfish, or other major allergens.

(* Excludes products listed in Annex II to Regulation (EU) 1169/2011.

INSTRUCTIONS FOR USE

Take 1 capsule per day, preferably on an empty stomach.

WARNINGS

Do not exceed the stated recommended daily dose. Food supplements should not be used as a substitute for a varied diet. Keep out of the reach of young children. Please consult your doctor prior to use.

STORAGE CONDITIONS

The product contains live probiotic micro-organisms sensitive to heat. Keep the product in a cool and dry place, at a temperature between 15–25°C, away from direct light.

DISCLAIMER

This leaflet is intended for informational purposes for consumers and healthcare professionals. Vitamin health claims are authorised by the European Commission under Regulation (EU) 432/2012. Probiotic effects relate to support of intestinal flora balance and wellbeing, not to the prevention or treatment of disease.

PACKAGE CONTENT

Printed cardboard box containing 3 blisters, with 10 capsules each containing 325 mg per capsule, and a leaflet.

MANUFACTURER

Manufactured by **Probiological S.p.A.**, Via E. Mattei 3, 28100 Novara, Italy

Distributed by **LIVFE**, 89 Level 0, Triq is-Siggiewi, Siggiewi SGW 2021, Malta – Europe

References:

- Aadil Bharwani, M. Firoz Mian, et al. Structural & functional consequences of chronic psychosocial stress on the microbiome and host. *Psychoneuroendocrinology*, 63, 217–227.
- Bauer ME, Teixeira AL. Inflammation in psychiatric disorders: what comes first? *Ann NY Academy of Sciences*, 2019;1437(1):57–67.
- Maes, M., Kubera, M., Leunis, J.-C., Berk, M., Geffard, M., & Bosmans, E. In depression, bacterial translocation may drive inflammatory responses, oxidative and nitrosative stress (ONS), and autoimmune responses directed against O6NS-damaged
- Marin IA, et al. Microbiota alteration is associated with the development of stress-induced despair behavior. *Scientific Reports* 2017 Mar 7, Article 43859.
- Mogna L et al. Assessment of the In Vitro Inhibitory Activity of Specific Probiotic Bacteria Against Different *Escherichia coli* strains. *J. Clin. Gastroenterol.* 2012;46 Suppl. S29–32.
- Deidda F, et al. How Probiotics may Kill Harmful Bacteria: The in vitro Activity against Some Haemolytic Strains. *J Prob Health*, 2020, Vol. 8 Iss.2 No: 216.
- Amoruso A. et al. A Systematic Evaluation of the Immunomodulatory and Functional Properties of Probiotic *Bifidobacterium Breve* BR03 (DSM 16604) *Lactobacillus plantarum* LP01 (LMG P-21021). *J Prob Health*, 2019.
- Magistrelli et al. Probiotics May Have Beneficial Effects in Parkinson's Disease: In vitro Evidence. *Frontiers in Immunology*, 2019.
- Saggioro, A. (2004). Probiotics in the treatment of irritable bowel syndrome. *Journal of Clinical Gastroenterology*, 2004.
- Internal Probiological's confidential reports
- Visciglia A, et al. Probiotics and Gut-Brain Axis: Insights on local and systemic mechanisms of action. Poster from the 12th Probiotics, Prebiotics & New Foods, Nutraceutical and Botanicals for Nutrition & Human and Microbiota Health, held in Rome on 12-14 September 2021.
- Marotta A, et al. Effects of Probiotics on Cognitive Reactivity, Mood, and Sleep Quality. *Front Psychiatry*. 2019 Mar 27;10:164.
- Calgario M, et al. Metabarcoding analysis of gut microbiota of healthy individuals reveals impact of probiotic and maltodextrin consumption. *Benef Microbes*. 2021 Apr 12;12(2):121–136.
- Walden KE, et al. A randomized controlled trial to examine the impact of a multi-strain probiotic on self-reported indicators of depression, anxiety, mood, and associated biomarkers. *Front Nutr*. 2023 Aug 31;10:1219313.
- Kerksick, et al. (2024). Multi-strain probiotic improves subjective sleep quality with no impact on body composition, hemodynamics, and physical activity. *Beneficial Microbes* 15(2), 179–192.
- Di Cesare, F. et al. Exploring the effects of probiotic treatment on urinary and serum metabolic profiles in healthy individuals. *Journal of Proteome Research* 2023 Dec 1;22(12), 3866–3878.